Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT05863442
NCT05863442RecruitingPhase 1

A First-in-human, Randomized, Double-blind, Parallel-group Study to Evaluate the PK, Safety, Tolerability, Immunogenicity, and PD Profile of a Single Intravenous Dose of TUR03 Compared With Soliris® in Healthy Adult Male Participants

Turgut Ardika PTY LTD1 site in 1 country120 target enrollmentStarted: April 10, 2023Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Recruiting
Enrollment
120
Locations
1
Primary Endpoint
PK similarity of TUR03 and Soliris following a single IV infusion in healthy participants
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This study is designed as a randomized, double-blind, parallel-group study to evaluate the PK, safety, tolerability, immunogenicity, and PD of TUR03 compared to Soliris, when administered as a single IV infusion in healthy adult male participants.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Basic Science
Masking
Double (Participant, Investigator)

Eligibility Criteria

Ages
18 Years to 45 Years (Adult)
Sex
Male
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Participants are eligible to be included in the study only if ALL of the following criteria apply:
  • •Capable of giving signed informed consent as described in Section 10.1, which includes compliance with the requirements and restrictions listed in the Informed Consent Form (ICF) and in this protocol.
  • •Participants assigned male at birth who are ≥18 years and ≤45 years old at the time of signing the ICF.
  • •Body weight ≥50 kg and ≤90 kg and body mass index (BMI) ≥18.00 kg/m2 and ≤30.00 kg/m2 at Screening and Day -
  • •Participants must be healthy as determined by the Investigator, based on medical history, physical examination, vital signs, ECG, and clinical laboratory evaluations at Screening and Day -1, as follows:
  • •Hematology and coagulation results within reference ranges.
  • •Liver function panel analyte values ≤1.5 × upper limits of normal (ULN), which include aspartate transaminase, alanine transaminase, and total bilirubin (for participants with Gilbert's Syndrome, total bilirubin ≤3.0 × ULN is allowed if direct bilirubin is ≤50%), alkaline phosphatase, and gamma glutamyl transferase at Screening.
  • •Urinalysis within reference ranges or showing no clinically significant findings.
  • •NOTE: One repeat of clinical laboratory tests is allowed at the discretion of the Investigator.
  • •Participants must have documented evidence of prior complete vaccination with meningococcal vaccines against N. meningitidis serogroup B at any time and against serogroups A, C, W, and Y within 5 years prior to Screening in line with local immunization requirements or must agree to be vaccinated against N. meningitidis during the study.
  • •Nonsterilized participants with partners of childbearing potential must agree to take appropriate contraceptive measures (as described in Section 10.4) from Day 1 until 5 months after IP administration and refrain from donating sperm during this period. NOTE: Participants with pregnant partners are excluded.
  • •Nonsmoker or occasional smoker, ie, smokes ≤10 cigarettes (or equivalent of tobacco- or nicotine-containing products) per week within 30 days prior to Screening and is able to abide by the smoking policy of the study site.
  • •Ability and willingness to abstain from alcohol from 48 hours before admission to the study site on Day -1, during in-house observation at the study site until discharge, and for 24 hours prior to ambulatory visits.

Exclusion Criteria

  • •Participants are excluded from the study if ANY of the following criteria apply:
  • •Known or suspected hereditary or acquired complement deficiency.
  • •History of meningococcal infection.
  • •History or evidence of a clinically significant disorder (including psychiatric disorders), condition, or disease that, in the opinion of the Investigator and Medical Monitor or designee, would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion. EXCEPTION: Fully resolved childhood asthma is not exclusionary.
  • •History of splenectomy.
  • •History of surgery or major trauma within 12 weeks of Screening, or surgery planned during the study.
  • •A recent history (within 1 week prior to IP administration) or presence or suspicion of current active systemic or local infection, a known risk for developing sepsis, and/or known active inflammatory condition, in the opinion of the Investigator.
  • •History of or current invasive malignancy (excluding basal or squamous cell carcinoma that has been fully resected with no evidence of metastatic disease for 1 year).
  • •History of ongoing seborrheic dermatitis or eczema.
  • •History of clinically significant headaches that, in the opinion of the Investigator, would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion.
  • •History of recurrent/chronic hemorrhages or any hemorrhage within 30 days prior to IP administration.
  • •History of a drug- or food-induced severe hypersensitivity reaction (eg, immunologic or nonimmunologic anaphylaxis).
  • •Known hypersensitivity reaction to penicillin and/or cephalosporin that, in the opinion of the Investigator, would pose a risk to participant safety.
  • •Known hypersensitivity to any component of TUR03 or Soliris, murine proteins, or other monoclonal antibodies.
  • •Known hypersensitivity to any component of meningococcal vaccines, including those containing diphtheria toxoid, or a life-threatening reaction after previous administration of a vaccine containing similar components.
  • •Hypertension at Screening or Day -1 (defined as a systolic blood pressure [BP] >140 mm Hg and/or a diastolic BP >90 mm Hg, confirmed by a single repeat measurement that same day) or a history of hypertension requiring pharmacological intervention.
  • •Proteinuria at Screening or Day -1 (with a urine dipstick value of 1+ or above)..
  • •Tests positive for human immunodeficiency virus (HIV 1 and 2), hepatitis B virus surface antigen, hepatitis B core antibody, or hepatitis C virus.
  • •Tests positive for tuberculosis (TB) using the QuantiFERON®-TB Gold test at Screening or, if indeterminant result on the first test, tests positive or indeterminant on repeat QuantiFERON-TB Gold test.
  • •Positive screen for alcohol by breath test and/or potential drugs of abuse by urine drug screen at Screening or Day -
  • •NOTE: One repeat screen is allowed at the discretion of the Investigator.
  • •History of alcohol or drug abuse or drug addiction (including cannabis products) within the last 12 months prior to Screening.
  • •Prior exposure to eculizumab or similar compounds (ie, a monoclonal antibody that specifically binds to the complement protein C5).
  • •Use of immunoglobulins or iron supplementation within 3 months prior to Screening.
  • •Use of any over-the-counter (OTC) medications, herbal remedies such as St. John's Wort extract, or prescription medications within 7 days or 5 half lives (whichever is longer) prior to IP administration. EXCEPTIONS: Vitamins, dietary supplements, and paracetamol (up to 4 g per day, but <1 g in 4 hours) for analgesia are not exclusionary.
  • •Use of other investigational drugs (or is currently using an investigational device) within 60 days or 5 half-lives (whichever is longer) prior to IP administration.
  • •Vaccination with a live vaccine within 30 days prior to IP administration, or vaccination with an inactivated vaccine or approved COVID-19 vaccine within 14 days prior to IP administration, or planning to get vaccinated during the study period. EXCEPTIONS: Receipt of required meningococcal vaccinations per protocol is not exclusionary.
  • •Veins unsuitable for venous blood collection.
  • •Donated blood (including blood products) or experienced loss of blood ≥500 mL within 30 days of Screening, or donated plasma within 7 days of Screening.
  • •Participant is a family member or employee of the Investigator or Sponsor.

Arms & Interventions

Soliris

Active Comparator

Intervention: Soliris 300 MG in 30 ML Injection (Drug)

TUR03

Experimental

Intervention: TUR03 300 MG in 30 ML Injection (Drug)

Outcomes

Primary Outcomes

PK similarity of TUR03 and Soliris following a single IV infusion in healthy participants

Time Frame: Day 1 - Day 57

The primary endpoint for PK similarity is AUC(0-inf).

Secondary Outcomes

  • AEs and AESI(Day 1 - Day 57)
  • Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Coagulation - Activated partial thromboplastin time(Day 1 - Day 57)
  • Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - ALT(Day 1 - Day 57)
  • Time to Cmax(Day 1 - Day 57)
  • Terminal half-life(Day 1 - Day 57)
  • Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Coagulation - International normalized ratio(Day 1 - Day 57)
  • Eculizumab serum concentration-time profile(Day 1 - Day 57)
  • Maximum serum concentration (Cmax)(Day 1- Day 57)
  • Area under the concentration-time curve from time zero to the last quantifiable concentration (AUClast)(Day 1- Day 57)
  • Total serum clearance of drug after intravenous administration(Day 1 - Day 57)
  • Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Hematology(Day 1 - Day 57)
  • Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - Creatinine(Day 1 - Day 57)
  • Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - ALP(Day 1 - Day 57)
  • Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - Chloride(Day 1 - Day 57)
  • Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - Calcium(Day 1 - Day 57)
  • Volume of distribution during terminal phase after intravenous administration(Day 1 - Day 57)
  • Terminal elimination rate constant(Day 1 - Day 57)
  • Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - Urea(Day 1 - Day 57)
  • Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - Gamma glutamyl transferase(Day 1 - Day 57)
  • Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Urinanalysis - Urobilinogen(Day 1 - Day 57)
  • Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Urinanalysis - Ketones(Day 1 - Day 57)
  • Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Coagulation - Prothrombin time(Day 1 - Day 57)
  • Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - AST(Day 1 - Day 57)
  • Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - Sodium(Day 1 - Day 57)
  • Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - Albumin(Day 1 - Day 57)
  • Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - Phosphate(Day 1 - Day 57)
  • Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - Carbon dioxide (bicarbonate)(Day 1 - Day 57)
  • Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - Glucose (fasting)(Day 1 - Day 57)
  • Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - Lactate dehydrogenase(Day 1 - Day 57)
  • Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - Total and direct bilirubin(Day 1 - Day 57)
  • Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Urinanalysis - Leukocytes(Day 1 - Day 57)
  • Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Urinanalysis - Red blood cells(Day 1 - Day 57)
  • Changes in vital signs - Pulse rate(Day 1 - Day 57)
  • Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - Total Protein(Day 1 - Day 57)
  • Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - Creatine kinase(Day 1 - Day 57)
  • Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - Potassium(Day 1 - Day 57)
  • Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - Triglycerides(Day 1 - Day 57)
  • Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Clinical chemistry - Cholesterol(Day 1 - Day 57)
  • Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Urinanalysis - pH(Day 1 - Day 57)
  • Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Urinanalysis - Nitrite(Day 1 - Day 57)
  • Changes in Electrocardiograms (ECG) - RR interval(Day 1 - Day 57)
  • Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Urinanalysis - Protein(Day 1 - Day 57)
  • Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Urinanalysis - Bilirubin(Day 1 - Day 57)
  • Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Urinanalysis - Glucose(Day 1 - Day 57)
  • Changes in vital signs - Body Temperature(Day 1 - Day 57)
  • Changes in Electrocardiograms (ECG) - PR interval(Day 1 - Day 57)
  • Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Urinanalysis - Specific gravity(Day 1 - Day 57)
  • Incidence of Treatment-Emergent changes in safety clinical laboratory parameters from baseline and Grade 3 laboratory abnormalities - Urinanalysis - Microscopy(Day 1 - Day 57)
  • Changes in vital signs - Blood Pressure(Day 1 - Day 57)
  • Comparison of the immunogenicity of TUR03 and Soliris following a single IV infusion in healthy participants - Frequency of antidrug antibodies (ADAs)(Day 1 - Day 57)
  • PD profile of TUR03 and Soliris - AUEC(0-1344) CH50(Day 1 - Day 57)
  • Changes in Electrocardiograms (ECG) - Heart rate(Day 1 - Day 57)
  • Changes in Electrocardiograms (ECG) - QRS duration(Day 1 - Day 57)
  • Comparison of the immunogenicity of TUR03 and Soliris following a single IV infusion in healthy participants - Antidrug antibody titers(Day 1 - Day 57)
  • PD profile of TUR03 and Soliris - Tmin CH50(Day 1 - Day 57)
  • Changes in Electrocardiograms (ECG) - QT interval(Day 1 - Day 57)
  • Comparison of the immunogenicity of TUR03 and Soliris following a single IV infusion in healthy participants - Neutralizing antibodies (NAbs)(Day 1 - Day 57)
  • PD profile of TUR03 and Soliris - Emin CH50(Day 1 - Day 57)
  • Number of patients with treatment-related adverse events as assessed by CTCAE v4.0 via physical examination(Day 1 - Day 57)
  • PD profile of TUR03 and Soliris - ABEC (0-1344) CH50(Day 1 - Day 57)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Terminated
Phase 3
Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®Melanoma
NCT06587451Sandoz52
Completed
Phase 3
Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian AncestryAsthma
NCT01498653GlaxoSmithKline313
Completed
Phase 2
A Study to Evaluate the Efficacy and Safety of Fixed Dose Combination of DW340 in Patients With Acute Low Back PainAcute Low Back Pain
NCT03424707Daewon Pharmaceutical Co., Ltd.45
Withdrawn
Phase 1
A SINGLE-DOSE, 2-ARM, PHARMACOKINETIC STUDY OF PF-06439535 (CN) AND EUROPEAN UNION SOURCED BEVACIZUMAB IN CHINESE HEALTHY MALE VOLUNTEERSPharmacokinetics
NCT04126044Pfizer
Completed
Phase 1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Atrosimab (ATM001) in Healthy VolunteersHealthy Volunteers
NCT04650126Baliopharm Pty Ltd42